Development and Validation of a Mass Spectrometry-Based Assay for the Molecular Diagnosis of Mucin-1 Kidney Disease
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
27157321
DOI
10.1016/j.jmoldx.2016.03.003
PII: S1525-1578(16)30020-4
Knihovny.cz E-resources
- MeSH
- Molecular Diagnostic Techniques * MeSH
- Genotype MeSH
- Mass Spectrometry methods standards MeSH
- Humans MeSH
- Mucin-1 genetics MeSH
- Mutation * MeSH
- Polycystic Kidney, Autosomal Dominant diagnosis genetics MeSH
- Workflow MeSH
- Reproducibility of Results MeSH
- Sensitivity and Specificity MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Mucin-1 MeSH
Mucin-1 kidney disease, previously described as medullary cystic kidney disease type 1 (MCKD1, OMIM 174000), is an autosomal dominant tubulointerstitial kidney disease recently shown to be caused by a single-base insertion within the variable number tandem repeat region of the MUC1 gene. Because of variable age of disease onset and often subtle signs and symptoms, clinical diagnosis of mucin-1 kidney disease and differentiation from other forms of hereditary kidney disease have been difficult. The causal insertion resides in a variable number tandem repeat region with high GC content, which has made detection by standard next-generation sequencing impossible to date. The inherently difficult nature of this mutation required an alternative method for routine detection and clinical diagnosis of the disease. We therefore developed and validated a mass spectrometry-based probe extension assay with a series of internal controls to detect the insertion event using 24 previously characterized positive samples from patients with mucin-1 kidney disease and 24 control samples known to be wild type for the variant. Validation results indicate an accurate and reliable test for clinically establishing the molecular diagnosis of mucin-1 kidney disease with 100% sensitivity and specificity across 275 tests called.
Broad Institute of MIT and Harvard Cambridge Massachusetts
Institute for Inherited Metabolic Disorders Charles University Prague Prague Czech Republic
Nephrology Section Wake Forest Baptist Medical Center Winston Salem North Carolina
References provided by Crossref.org
A Novel Monoallelic ALG5 Variant Causing Late-Onset ADPKD and Tubulointerstitial Fibrosis
Maternal health and pregnancy outcomes in autosomal dominant tubulointerstitial kidney disease
Autosomal dominant tubulointerstitial kidney disease: A review
Outcomes of patient self-referral for the diagnosis of several rare inherited kidney diseases
Autosomal dominant tubulointerstitial kidney disease (ADTKD) in Ireland